We are live on ! Find out more
RNTX

Rein Therapeutics

32 hedge funds and large institutions have $16.3M invested in Rein Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

21% more capital invested

Capital invested by funds: $13.5M → $16.3M (+$2.79M)

10% more funds holding

Funds holding: 2932 (+3)

1.42% less ownership

Funds ownership: 22.67%21.25% (-1.4%)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Holders
32
Holders Change
+3
Holders Change %
+10.34%
% of All Funds
0.46%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
6
Reduced
8
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
26
Bank of America
North Carolina
$1.01K -$19 -7 -2%
TRCT
27
Tower Research Capital (TRC)
New York
$860 -$9.68K -3,621 -94%
Fidelity Investments
28
Fidelity Investments
Massachusetts
$825
HCP
29
Hexagon Capital Partners
Arkansas
$754
GPFA
30
Game Plan Financial Advisors
Ohio
$89
KC
31
Kepos Capital
New York
-$294K -106,000 Closed
UBS Group
32
UBS Group
Switzerland
-$8.71K -3,145 Closed
AW
33
Avion Wealth
Texas
+$535 +200 New

RNTX Hedge Fund Activity: Q3 2024 in Review

32 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2024, worth a combined $16.3M — up 21% from $13.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new RNTX positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Prosight Management, adding an estimated $286K. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), cutting an estimated $1M.

  • 32 institutional investors held Rein Therapeutics (RNTX) as of Q3 2024, up from 29 in Q2 2024.
  • Funds reported $16.3M of Rein Therapeutics stock for Q3 2024, up 21% quarter-over-quarter.
  • 5 funds opened new Rein Therapeutics positions in Q3 2024 and 2 closed out, a net change of +3 holders.
  • The largest Rein Therapeutics buyer in Q3 2024 was Prosight Management, an estimated $286K added.
  • The largest Rein Therapeutics seller in Q3 2024 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $1M sold.

Based on aggregated 13F filings for Q3 2024.